scholarly journals Non-Marginal Cost-Benefit Analysis and the Tyranny of Discounting

2013 ◽  
Author(s):  
Koen Vermeylen
Keyword(s):  
Marginal Cost ◽  
Cost Benefit Analysis ◽  
Cost Benefit ◽  
Benefit Analysis

scholarly journals Cost-benefit analysis of pharmacist interventions over 36 months in a university hospital

2020 ◽  
Vol 54 ◽  
pp. 94
Author(s):  
Maurilio de Souza Cazarim ◽  
João Paulo Vilela Rodrigues ◽  
Priscila Santos Calcini ◽  
Thomas Einarson ◽  
Leonardo Régis Leira Pereira
Keyword(s):  
Marginal Cost ◽  
Cost Benefit Analysis ◽  
Cost Benefit ◽  
University Hospital ◽  
Cost Ratio ◽  
Benefit Analysis ◽  
Net Benefit ◽  
Hospital Perspective ◽  
Benefit Cost Ratio ◽  
Tertiary Teaching

OBJECTIVE: To perform a cost-benefits analysis of a clinical pharmacy (CP) service implemented in a Neurology ward of a tertiary teaching hospital. METHODS: This is a cost-benefit analysis of a single arm, prospective cohort study performed at the adult Neurology Unit over 36 months, which has evaluated the results of a CP service from a hospital and Public Health System (PHS) perspective. The interventions were classified into 14 categories and the costs identified as direct medical costs. The results were analyzed by the total and marginal cost, the benefit-cost ratio (BCR) and the net benefit (NB). RESULTS: The total 334 patients were followed-up and the highest occurrence in 506 interventions was drug introduction (29.0%). The marginal cost for the hospital and avoided cost for PHS was US$182±32 and US$25,536±4,923 per year; and US$0.55 and US$76.4 per patient/year. The BCR and NB were 0.0, -US$26,105 (95%CI -31,850 – -10,610), -US$27,112 (95%CI -33,160–11,720) for the hospital and; 3.0 (95%CI 1.97–4.94), US$51,048 (95%CI 27,645–75,716) and, 4.6 (95%CI 2.24–10.05), US$91,496 (95%CI 34,700–168,050; p < 0.001) for the PHS, both considering adhered and total interventions, respectively. CONCLUSIONS: The CP service was not directly cost-benefit at the hospital perspective, but it presented savings for forecast cost related to the occurrence of preventable morbidities, measuring a good cost-benefit for the PHS.

Modelling pesticide risk: A marginal cost–benefit analysis of an environmental buffer-zone programme

2010 ◽  
Vol 27 (2) ◽  
pp. 653-661 ◽  
Author(s):  
Stefan Sieber ◽  
David Pannell ◽  
Klaus Müller ◽  
Karin Holm-Müller ◽  
Peter Kreins ◽  
...  
Keyword(s):  
Marginal Cost ◽  
Cost Benefit Analysis ◽  
Cost Benefit ◽  
Buffer Zone ◽  
Benefit Analysis

Cost–benefit analysis of China’s Intended Nationally Determined Contributions based on carbon marginal cost curves

2018 ◽  
Vol 227 ◽  
pp. 415-425 ◽  
Author(s):  
Xi Yang ◽  
Fei Teng ◽  
Xiaoqian Xi ◽  
Egor Khayrullin ◽  
Qi Zhang
Keyword(s):  
Marginal Cost ◽  
Cost Benefit Analysis ◽  
Cost Benefit ◽  
Benefit Analysis ◽  
Cost Curves ◽  
Nationally Determined Contributions ◽  
Marginal Cost Curves

scholarly journals On Non-Marginal Cost-Benefit Analysis

2010 ◽  
Author(s):  
Simon Dietz ◽  
Cameron J. Hepburn
Keyword(s):  
Marginal Cost ◽  
Cost Benefit Analysis ◽  
Cost Benefit ◽  
Benefit Analysis

Principles of Cost-Benefit Analysis for Developing Countries

1996 ◽  
Author(s):  
Caroline L. Dinwiddy ◽  
Francis J. Teal
Keyword(s):  
Developing Countries ◽  
Cost Benefit Analysis ◽  
Cost Benefit ◽  
Benefit Analysis
Sign in / Sign up

Export Citation Format

Share Document